Clinilabs selects NewCardio's QTinnoŽ solution for phase I trial
NewCardio, a cardiovascular diagnostic solutions developer, has reported that its strategic partner, Clinilabs, will utilize QTinnoŽ, NewCardio's automated cardiac safety solution, to conduct a phase I trial of an investigational new drug under development for a central nervous system (CNS) indication.
Clinilabs is a full-service contract research organization that provides early-phase and specialty clinical drug development services to industry. Clinilabs has integrated QTinno into its current core lab offerings as part of its strategic initiative to deliver a full portfolio of cardiac safety and cardiac core laboratory services to industry. Providing fully automated ECG analysis as an integrated service offering, empowered by QTinno, enables Clinilabs to provide the complete range of ECG processing services now requested by pharma companies interested in assessing the cardiac safety of drugs in development.
NewCardio's 3D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead ECG. NewCardio's lead product is QTinno, a software suite that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety markers for the pharmaceutical industry and drug regulators. The `ompany believes that QTinno, a software-based, analytical technology is the industry's leading solution for the delivering accurate and precise analysis of ECGs in a fully automated process to determine cardiac toxicity during drug development, with the added benefit of significant time and cost efficiencies.